DOCSLIB.ORG

Novel Chiral LC Methods for the Enantiomeric Separation of Bicalutamide and Thalidomide on Amylose Based Immobilized CSP

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Novel Chiral LC Methods for the Enantiomeric Separation of Bicalutamide and Thalidomide on Amylose Based Immobilized CSP Current Pharmaceutical Analysis, 2011, 7, 47-53 47 Novel Chiral LC Methods for the Enantiomeric Separation of Bicalutamide and Thalidomide on Amylose Based Immobilized CSP I.V. Soma Raju1,*, P. Raghuram2,* and J. Sriramulu2 1Invagen Pharmaceuticals Inc. New York, NY, USA 2Department of Chemistry, Sri Krishna Devaraya University, Anantapur-515003, India Abstract: Fast chiral liquid chromatographic methods are developed for the separation of bicalutamide and thalidomide enantiomers in bulk drug samples in an elution time of about 15 min. The chromatographic separation was carried out on various solvents using an amylose 3,5-dimethylphenylcarbamate immobilized onto silica gel (Chiralpak-IA). The resolu- tion (Rs) between the enantiomers is found to be greater than 1.5 in the developed method. Chiralpak-IA column played a key role in achieving chromatographic resolution between the enantiomers and also in enhancing chromatographic effi- ciency. The column’s compatability to non standard chromatographic solvents is checked and found suitable. Keywords: Bicalutamide, Thalidomide, Chiralpak-IA, Enantiomeric separation. INTRODUCTION widely used is liquid chromatography (LC) employing a chiral stationary phase (CSP) [5-7]. Bicalutamide (Fig. 1.1) is an oral non-steroidal anti- androgen used in the treatment of prostate cancer and hirsu- O O tism [1]. And thalidomide (Fig. 1.2) is a sedative-hypnotic, HN and multiple myeloma medication [2]. These two active O N pharmaceutical substances are racemic mixtures. N O Fig. (1.2). Thalidomide: (RS)-2-(2,6-dioxopiperidin-3-yl)-1H- F isoindole-1,3(2H)-dione F F O Polysaccharide derived chiral stationary phases (CSPs) HN have been recognized as the most powerful packing materi- als for the chromatographic separation of enantiomers in OH analytical and preparative applications due to their broad O SO application field and their remarkable loading capacity [8- 17]. Due to their coated nature, these CSPs can only be used with a limited range of solvents such as the polar solvents (e.g. acetonitrile, alcohols) or non-polar solvents (e.g. al- kanes) in combination with some polar components as modi- F fiers (mainly alcohols). Solvents with intermediate polarities, Fig. (1). Structure and label of bicalutamide, thalidomide and trans- such as methyl t-butyl ether, ethyl acetate, tetrahydrofuran, Stilbene Oxide. acetone, 1,4-dioxane and chlorinated solvents can partially or Fig. (1.1). Bicalutamide:N-[4-cyano-3-(trifluoromethyl)phenyl]-3- totally dissolve the above CSPs. Therefore, they must be [(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide excluded in the optimization of chromatographic parameters Enantiomers of racemic drugs often differ in pharma- on these CSPs. Immobilization of a polysaccharide deriva- cokinetic behavior or pharmacological action [3]. The devel- tive on the support is an evolutionary strategy to make a CSP opment of analytical methods for the quantitative analysis of compatible with the whole range of organic solvents, which chiral materials and for the assessment of enantiomeric pu- will consequently extend its application scope [18]. rity is extremely challenging due to the fact that enantiomers Chiralpak-IA (amylose 3,5-dimethylphenylcarbamate posses virtually identical properties [4]. Although many ana- immobilized onto silica gel) has been extensively investi- lytical techniques can be employed to achieve this, the most gated and proved to be versatile in enantiomeric separation and excellent in solvent compatibility. In the present work, *Address correspondence to these authors at the Invagen Pharmaceuticals the key role of mobile phase in the enantiomeric selectivity Inc. New York, NY, USA; Tel: 917 434 0797; Fax: 631 231 4288; shown by this immobilized CSP is checked. A structured E-mails: [email protected] approach for solvent compatibility is followed [19] and also Department of Chemistry, Sri Krishna Devaraya University, Anantapur- the use of non standard solvents is verified as stated by 515003, India; E-mail: [email protected] 1573-4129/11 $58.00+.00 © 2011 Bentham Science Publishers Ltd. 48 Current Pharmaceutical Analysis, 2011, Vol. 7, No. 1 Raju et al. manufacturer [20]. These two APIs are selected as they be- 1.2.2. Chromatographic Conditions long to similar therapeutic category. The chromatographic conditions are optimized using a Few analytical methods had been reported in the litera- Chiralpak-IA column. The column temperature is main- ture for enantiomeric separation of bicalutamide and tha- tained at 25°C and the detection is monitored at a wave- lidomide by HPLC but all these methods are developed on length bicalutamide 270 nm and thalidomide 210 nm (Table cellulose based (Chiralpak AD-H and Chiralcel OD-H) and 1). The injection volume is 20 μL. Methanol is used as diluent. whelk O1 columns [21-25]. So far, to our present knowledge 1.2.3. Preparation of Sample Solution no chiral HPLC methods are reported in the literature for the enantiomeric separation of bicalutamide and thalidomide on Stock solutions of bicalutamide and thalidomide (1000 Chiralpak-IA [immobilized chiral stationary phase]. This g mL-1) are prepared individually by dissolving appropriate paper deals with method development for the enantiomeric amount of the substances in the diluent. The analyte concen- separation on immobilized stationary phases for bicalu- tration of 200 g mL-1 for bicalutamide and 50 g mL-1 for tamide and thalidomide active pharmaceutical ingredients. thalidomide. Working solutions of bicalutamide and tha- Compatibility of dichloromethane, ethyl acetate and tetrahy- lidomide are prepared in diluents. drofuran with Chiralpak-IA is checked. 1.3. Method Development and Optimization 1. EXPERIMENTAL DESIGN 1.3.1. Introduction 1.1. Chemicals In principle all miscible solvents can be used with an immobilized CSP either in their pure form or as mobile Samples of bicalutamide and thalidomide are obtained phase components. The exhaustive investigation of various from Hetero Labs Ltd., Hyderabad, India. HPLC grade n- solvents for their general behavior in enantioselective separa- hexane, dichloromethane, isopropyl alcohol, methanol, etha- tions is undoubtedly essential in the mobile phase selection. nol, acetonitrile, tetrahydrofuran, ethyl acetate and methyl t- A large series of organic solvents have been investigated. It butyl ether are purchased from Merck, Darmstadt, Germany. is found that, among the usual solvents for chromatography, Trans-stilbene oxide is purchased from Fluka, Germany. methyl t-butyl ether, CH2Cl2, tetrahydrofuran, ethyl acetate, together with the standard solvents are those with the highest 1.2. Procedure potential in terms of enantioselectivity on Chiralpak® IA 1.2.1. Equipment [19]. Although this CSP can afford more or less comparable separations with standard mobile phases as Chiralpak® AD, The LC System, used for method development, and its real interest lies in the use of non-standard ones. method verification are Shimadzu 2010 & Agilent 1100 Model Systems with variable UV detector. The output signal The method development is done with standard solvents is monitored and processed using LCsolution & chemstation like normal phase solvents, i.e polar solvents and reverse software on pentium computer. phase solvents and then with non standard solvents. The chiral column used in method development Chiral- 1.3.2. Optimization Strategy (Performance Control Analysis) pak -IA is manufactured by Daicel Chemical Industries Ltd; The performance of the column is checked by its ability Japan having 5 m particle size in 250 x 4.6 mm dimension. to separation of enantiomers in trans-stilbene oxide (Fig. 1.3) Table 1. Optimized Conditions for the Analysis of Bicalutamide and Thalidomide Enantiomers Compound Bicalutamide Thalidomide Wave length 270 nm 210 nm Flow 1.0 mL/min Temperature 25°C Diluent Methanol Mobile phase - 1 Methanol: Hexanes: Tetrahydrofuran (30:50:20 v/v) Mobile phase - 2 Dichloromethane: Methanol: n-Hexane (40:20:40 v/v ) Mobile phase - 3 Ethyl Acetate: Methanol: n-Hexane (30:55:15v/v ) Mobile phase - 4 Methyl t-butyl ether: n-Hexane: Methanol (50:10:40 v/v) Novel Chiral LC Methods for the Enantiomeric Separation Current Pharmaceutical Analysis, 2011, Vol. 7, No. 1 49 2.2. Multi Wavelength Analysis The multi wavelength analysis is done to analyze bicalu- tamide and thalidomide together and is found suitable. O Wavelength program is as given below. Chromatogram is Fig. (1.3). Trans-Stilbene Oxide. enclosed for mobile phase combination 1. (Figs. 2 and 3). with a criterion of resolution not less than 2.0 and tailing factor between 0.8 to 2 and theoretical plates not less than Time(min) Wavelength(nm) 4000 for the enantiomeric peaks. Performance is measured 0 270 before and after the experiments and at regular intervals. The set criterion for performance control was met before and 5.0 210 after the experiments. 1.3.3. Selection of Mobile Phase Samples of bicalutamide and thalidomide analysed in 4 optimized mobile phases resulted in 50 : 50 enantiomers as The investigation of above listed solvents for their gen- expected theoretically meeting system suitability criterion. eral behavior in enantio selective separations is made in the The column is found working satisfactorily after analysis mobile phase selection [19]. The method development is using standard solvents and non standard chromatographic done with standard solvents i.e normal phase solvents [polar solvents. solvents] and reverse phase solvents and then with non stan- dard solvents. The target is to achieve resolution between 2.3. Analytical Method Validation two enantiomers of not less than 1.5 with and tailing factor 2.3.1. Limit of Quantification (LOQ) between 0.8 to 2.0 and theoretical plates not less than 4000. The quantitation limit of an individual analytical proce- 1.3.4. Using Polar and Non Polar Solvents dure is the lowest amount of analyte in a sample which can The trials are unsuccessful in n-hexane combination with be quantitatively determined with suitable precision and ac- -1 ethanol and IPA in which either peaks are not eluted or reso- curacy. LOQ was found to be 0.1g mL for bicalutamide -1 lution is not achieved.
Load more

Recommended publications
  • Thalidomide Celgene Pregnancy Prevention Programme Information
    TCPPP Healthcare Professional Booklet Thalidomide Celgene ® Pregnancy Prevention Programme Information for Healthcare Professionals ® Prescribing or Dispensing Thalidomide Celgene Celgene representative contact details: AM Mangion Ltd, Regulatory Office, “Mangion Building”, New Street Off Valletta Road, Luqa. Phone: +356 239 76333 Fax: +356 239 76123 Email: [email protected] Medical Information queries: [email protected] 2014 © Celgene Corporation Page 1 of 19 RMP/THA/001/14-03/M TCPPP Healthcare Professional Booklet This booklet is intended for healthcare professionals involved in prescribing or dispensing Thalidomide Celgene ®, and contains information about: Preventing harm to unborn babies: If Thalidomide Celgene® is taken during pregnancy it can cause severe birth defects or death to an unborn baby. Other side effects of Thalidomide Celgene®: The most commonly observed adverse reactions associated with the use of Thalidomide Celgene® in combination with melphalan and prednisone are: neutropenia, leukopenia, constipation, somnolence, paraesthesia, peripheral neuropathy, anaemia, lymphopenia, thrombocytopenia, dizziness, dysaesthesia, tremor and peripheral oedema. Further information and recommended precautions can be found in the Thalidomide Celgene® Summary of Product Characteristics (SmPC). Thalidomide Celgene® Pregnancy Prevention Programme: This Programme is designed to make sure that unborn babies are not exposed to Thalidomide Celgene®. It will provide you with information about how to follow the programme and explain your responsibilities. This booklet will help you understand these problems and make sure you know what to do before prescribing and dispensing Thalidomide Celgene®. For your patients’ own health and safety, please read this booklet carefully. You must ensure that your patients fully understand what you have told them about Thalidomide Celgene® before starting treatment.
    [Show full text]
  • Study Protocol and Statistical Analysis Plan
    Official Title: A Phase III, Multicenter, Randomized Study of Atezolizumab (Anti-PD- L1 Antibody) in Combination With Enzalutamide Versus Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer After Failure of an Androgen Synthesis Inhibitor and Failure of, Ineligibility for, or Refusal of a Taxane Regimen NCT Number: NCT03016312 Document Date: Protocol Version 8: 14 February 2020 PROTOCOL TITLE: A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTIPD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN PROTOCOL NUMBER: CO39385 VERSION NUMBER: 8 EUDRACT NUMBER: 2016-003092-22 IND NUMBER: 131196 TEST PRODUCTS: Atezolizumab (RO5541267) and enzalutamide MEDICAL MONITOR: , M.D., Ph.D. SPONSOR: F. Hoffmann-La Roche Ltd DATE FINAL: Version 1: 29 September 2016 DATES AMENDED: Version 2: 7 March 2017 Version 3: 4 April 2017 Version 4: 29 June 2017 Version 5: 2 March 2018 Version 6: 23 August 2018 Version 7: 5 August 2019 Version 8: See electronic date stamp below. PROTOCOL AMENDMENT APPROVAL Date and Time (UTC) Title Approver's Name 14-Feb-2020 17:27:37 Company Signatory CONFIDENTIAL This clinical study is being sponsored globally by F. Hoffmann-La Roche Ltd of Basel, Switzerland. However, it may be implemented in individual countries by Roche’s local affiliates, including Genentech, Inc. in the United States. The information contained in this document, especially any unpublished data, is the property of F. Hoffmann-La Roche Ltd (or under its control) and therefore is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Ethics Committee or Institutional Review Board.
    [Show full text]
  • Cancer Drug Pharmacology Table
    CANCER DRUG PHARMACOLOGY TABLE Cytotoxic Chemotherapy Drugs are classified according to the BC Cancer Drug Manual Monographs, unless otherwise specified (see asterisks). Subclassifications are in brackets where applicable. Alkylating Agents have reactive groups (usually alkyl) that attach to Antimetabolites are structural analogues of naturally occurring molecules DNA or RNA, leading to interruption in synthesis of DNA, RNA, or required for DNA and RNA synthesis. When substituted for the natural body proteins. substances, they disrupt DNA and RNA synthesis. bendamustine (nitrogen mustard) azacitidine (pyrimidine analogue) busulfan (alkyl sulfonate) capecitabine (pyrimidine analogue) carboplatin (platinum) cladribine (adenosine analogue) carmustine (nitrosurea) cytarabine (pyrimidine analogue) chlorambucil (nitrogen mustard) fludarabine (purine analogue) cisplatin (platinum) fluorouracil (pyrimidine analogue) cyclophosphamide (nitrogen mustard) gemcitabine (pyrimidine analogue) dacarbazine (triazine) mercaptopurine (purine analogue) estramustine (nitrogen mustard with 17-beta-estradiol) methotrexate (folate analogue) hydroxyurea pralatrexate (folate analogue) ifosfamide (nitrogen mustard) pemetrexed (folate analogue) lomustine (nitrosurea) pentostatin (purine analogue) mechlorethamine (nitrogen mustard) raltitrexed (folate analogue) melphalan (nitrogen mustard) thioguanine (purine analogue) oxaliplatin (platinum) trifluridine-tipiracil (pyrimidine analogue/thymidine phosphorylase procarbazine (triazine) inhibitor)
    [Show full text]
  • Adverse Effects in Women: Implications for Drug Development and Regulatory Policies
    Review For reprint orders, please contact [email protected] Adverse effects in women: implications for drug development and regulatory policies Expert Rev. Clin. Pharmacol. 4(4), 453–466 (2011) Ameeta Parekh†1, The requirement to establish safety of drugs prior to marketing has been in place since 1938 by Emmanuel O Fadiran1, the US Food, Drug and Cosmetic Act and is by no means a new concept. The efficacy regulations Kathleen Uhl2 were enacted in 1962 via the Kefauver–Harris Amendment and the drug approval process has and Douglas C evolved thereafter. The assessment of safety and efficacy of drug products is made by 2 pharmaceutical companies during drug development, which then goes through a regulatory Throckmorton review by the US FDA for the determination of market approval or nonapproval. The drug 1Food and Drug Administration, development and regulatory approval processes have endured close ongoing scrutiny by Office of Women’s Health, 10903 New Hampshire Avenue, regulatory bodies, the public, US Congress and academic and private organizations and, as a Silver Spring, MD 10993, USA result, have ensured continual refinement. Over the years, evidence has been emerging on varied 2Food and Drug Administration, drug responses in subgroup populations, and the underlying biology associated with age, race Center for Drug Evaluation and and sex as demographic variables have been examined. The resulting growing knowledge of Research, Office of Medical Policy, 10903 New Hampshire Avenue, disease burden, treatment response and disparate outcomes has generated opportunities to Silver Spring, MD 10993, USA streamline and improve treatment outcomes in these populations. This article discusses the †Author for correspondence: historical context of women’s participation in clinical drug trials submitted to the FDA for Tel.: +1 301 796 9445 regulatory review and approval purposes.
    [Show full text]
  • New Drugs Are Not Enough‑Drug Repositioning in Oncology: an Update
    INTERNATIONAL JOURNAL OF ONCOLOGY 56: 651-684, 2020 New drugs are not enough‑drug repositioning in oncology: An update ROMINA GABRIELA ARMANDO, DIEGO LUIS MENGUAL GÓMEZ and DANIEL EDUARDO GOMEZ Laboratory of Molecular Oncology, Science and Technology Department, National University of Quilmes, Bernal B1876, Argentina Received August 15, 2019; Accepted December 16, 2019 DOI: 10.3892/ijo.2020.4966 Abstract. Drug repositioning refers to the concept of discov- 17. Lithium ering novel clinical benefits of drugs that are already known 18. Metformin for use treating other diseases. The advantages of this are that 19. Niclosamide several important drug characteristics are already established 20. Nitroxoline (including efficacy, pharmacokinetics, pharmacodynamics and 21. Nonsteroidal anti‑inflammatory drugs toxicity), making the process of research for a putative drug 22. Phosphodiesterase-5 inhibitors quicker and less costly. Drug repositioning in oncology has 23. Pimozide received extensive focus. The present review summarizes the 24. Propranolol most prominent examples of drug repositioning for the treat- 25. Riluzole ment of cancer, taking into consideration their primary use, 26. Statins proposed anticancer mechanisms and current development 27. Thalidomide status. 28. Valproic acid 29. Verapamil 30. Zidovudine Contents 31. Concluding remarks 1. Introduction 2. Artesunate 1. Introduction 3. Auranofin 4. Benzimidazole derivatives In previous decades, a considerable amount of work has been 5. Chloroquine conducted in search of novel oncological therapies; however, 6. Chlorpromazine cancer remains one of the leading causes of death globally. 7. Clomipramine The creation of novel drugs requires large volumes of capital, 8. Desmopressin alongside extensive experimentation and testing, comprising 9. Digoxin the pioneer identification of identifiable targets and corrobora- 10.
    [Show full text]
  • Thalidomide and Pregnancy
    Thalidomide This sheet talks about exposure to thalidomide in pregnancy and while breastfeeding. This information should not take the place of medical care and advice from your healthcare provider. What is thalidomide? Thalidomide is a sedative that also changes the body’s immune response and reduces the ability of the body to grow new blood vessels. Thalidomide was one of the first medications recognized to cause birth defects in humans. Thalidomide was not released in the United States until 1998. It has been used to treat several medical conditions, such as leprosy, certain types of cancer, inflammatory bowel disease and complications from HIV infection. It is sold under the brand name Thalomid®. I take thalidomide. Can it make it harder for me to get pregnant? There has been one small study that looked at women who had inflammatory bowel disease and were treated with thalidomide. This study suggested exposure to thalidomide might reduce the number of eggs in the ovaries. It is not clear if this would affect fertility. Further study is needed. Because thalidomide can cause birth defects when taken early in pregnancy, often before a woman recognizes that she is pregnant, it is very important that effective methods of birth control be used correctly and all of the time. It is recommended that two different and reliable methods of birth control be used if a woman is taking thalidomide. Thalidomide may decrease the effectiveness of oral contraceptives (birth control pills). The manufacturer developed the REMS (Risk Evaluation and Mitigation Strategy) program (formerly known as the S.T.E.P.S.® program) to help prevent exposure to pregnant women.
    [Show full text]
  • Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: from Discovery to Implementation
    G C A T T A C G G C A T genes Review Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation Reka Varnai 1,2, Leena M. Koskinen 3, Laura E. Mäntylä 3, Istvan Szabo 4,5, Liesel M. FitzGerald 6 and Csilla Sipeky 3,* 1 Department of Primary Health Care, University of Pécs, Rákóczi u 2, H-7623 Pécs, Hungary 2 Faculty of Health Sciences, Doctoral School of Health Sciences, University of Pécs, Vörösmarty u 4, H-7621 Pécs, Hungary 3 Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, FI-20520 Turku, Finland 4 Institute of Sport Sciences and Physical Education, University of Pécs, Ifjúság útja 6, H-7624 Pécs, Hungary 5 Faculty of Sciences, Doctoral School of Biology and Sportbiology, University of Pécs, Ifjúság útja 6, H-7624 Pécs, Hungary 6 Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania 7000, Australia * Correspondence: csilla.sipeky@utu.fi Received: 17 June 2019; Accepted: 5 August 2019; Published: 8 August 2019 Abstract: Prostate cancer is the fifth leading cause of male cancer death worldwide. Although docetaxel chemotherapy has been used for more than fifteen years to treat metastatic castration resistant prostate cancer, the high inter-individual variability of treatment efficacy and toxicity is still not well understood. Since prostate cancer has a high heritability, inherited biomarkers of the genomic signature may be appropriate tools to guide treatment. In this review, we provide an extensive overview and discuss the current state of the art of pharmacogenomic biomarkers modulating docetaxel treatment of prostate cancer. This includes (1) research studies with a focus on germline genomic biomarkers, (2) clinical trials including a range of genetic signatures, and (3) their implementation in treatment guidelines.
    [Show full text]
  • Thalidomide Pregnancy Prevention Programme Information For
    Thalidomide Healthcare Professional Brochure Celgene Corporation Thalidomide Pregnancy Prevention Programme Information for Healthcare Professionals Prescribing or Dispensing Thalidomide RMP/THA/001/20-07/M 1 Thalidomide Healthcare Professional Brochure Celgene Corporation This brochure is intended for healthcare professionals involved in prescribing or dispensing thalidomide, and contains information about: Preventing harm to unborn babies: If thalidomide is taken during pregnancy it can cause severe birth defects or death to an unborn baby. Other side effects of thalidomide: Ischaemic heart disease including myocardial infarction. Further information and recommended precautions can be found in the thalidomide Summary of Product Characteristics (SmPC). Thalidomide Pregnancy Prevention Programme: This Programme is designed to prevent unborn babies being exposed to thalidomide. It will provide you with information about how to follow the programme and explain your responsibilities. It is a requirement of the Pregnancy Prevention Programme that all healthcare professionals ensure that they have read and understood this brochure To ensure your patients’ safety, please read this brochure carefully. You must ensure that your patients fully understand what you have told them about thalidomide before starting treatment. RMP/THA/001/20-07/M 2 Thalidomide Healthcare Professional Brochure Celgene Corporation CONTENTS Introduction ..................................................................................... 4 Thalidomide ..................................................................................................................
    [Show full text]
  • Volume , Number
    Volume 3, Number 6 for health professionals who care for cancer patients June 2000 were intended for patients who are treated as I NSIDE THIS ISSUE inpatient for the first two of five daily treatments. It . Alert! – GUEP Pre-printed Order must be ensured that the full 5 days of Misinterpretation, LUCAV, LUALTE, LUALTL chemotherapy is given, not just the final three days. Pre-printed Order Error Note that both GUEP and GUBEP protocols are . Protocol Update – BRAVCAP, BRAVTRAP, five-day treatments. GUVIP2, HNFUA, LYCDA, SCHYPCAL, UBRAVTR The GUEP pre-printed orders have been revised to . Cancer Management Manual – Genitourinary, prevent potential misinterpretation and treatment Lymphoma, Nutritional Care error. Other pre-printed orders are being reviewed . Pre-Printed Order Update – Lymphoma New to identify if similar potential for misinterpretation Patient Consultation, GUMVAC, LUCAV, exists. LUALTE, LUALTL, LYECV, LYACOP6, LYACOP12, LYCOPA LUCAV, LUALTE, LUALTL Pre-printed . Drug Update – Dacarbazine, Flutamide, Oral Orders Error The Vancouver Cancer Centre pre- Phosphate, Thalidomide, Trastuzumab printed orders (last revised 8 March) for these (Herceptin®) protocols, titled LUCAV, LUALTE-CAV, . Continuing Education – Canadian Association th LUALTL-CAV, respectively, contain a significant of Nurses in Oncology 12 Annual Conference, error. There is a statement that the chemotherapy is BCCA Annual Clinical Cancer Conference Days 1-3. This should be a Day 1 dose only. Comments to the Editor – Scent-free Workplace Please discard all previous versions and replace with new versions dated 26 May 2000. FAX request form and IN TOUCH phone list are provided if additional information is needed. PROTOCOL UPDATE Protocol codes for treatments requiring ALERT! “Undesignated Indication” approval prior to use are It has come to our attention that one pre-printed prefixed with the letter U.
    [Show full text]
  • Thalidomide in Leprosy Do Not Require Any Specific Treatment Except with Some Thalidomide: a Few Years Later, However, the Analgesics/Antipyretics
    FEATURE The Return of Thalidomide in Leprosy do not require any specific treatment except with some Thalidomide: A few years later, however, the analgesics/antipyretics. In those drug thalidomide was suffering ENL associated neuritis, New Uses and reintroduced as treatment for a the drug of choice is Renewed complication of leprosy called prednisolone. For chronic erythema nodosum leprosum recurrent reactions the drug of Concerns (ENL). Although the evidence choice is clofazimine. Dr V Pannikar, Medical was not fully established, very soon the drug was heralded as Thalidomide in other Officer, Communicable the drug of choice for the indications Diseases (Leprosy management of ENL reactions in Group), WHO leprosy and regulatory The above points clearly authorities granted exemption demonstrate that there is no place for thalidomide in leprosy. History from licensing requirements to enable doctors to obtain limited But very often this disease is Thalidomide or α-(N- supplies of thalidomide under used as an entry point to phthalimido) glutarimide was strictly controlled circumstances reintroduce thalidomide for a marketed in 1957 for morning for use in named patients. multitude of other indications. sickness and nausea and soon Thalidomide's effectiveness in Millions of treatments are being became the ‘drug of choice to minimizing symptoms of ENL was prescribed annually and almost help pregnant women’. It went mainly due to its antipyretic all of it is for non-leprosy into general use by the following action. Its effectiveness in conditions including cancer year and was widely prescribed controlling neuritis, the major treatment and use in HIV. There in Europe, Australia, Asia, Africa cause of permanent disabilities in are limited trials demonstrating 1 leprosy, was limited.
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]
  • Recent Advances in the Management of Hormone Refractory Prostate Cancer
    Korean J Uro-Oncol 2004;2(3):147-153 Recent Advances in the Management of Hormone Refractory Prostate Cancer Mari Nakabayashi, William K. Oh Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA A typical treatment strategy after AAWD is to use secondary INTRODUCTION hormonal manipulations, although studies have not yet demonstrated a survival benefit with this class of treatment. Prostate cancer is the most common cancer in men in the Options in this category include (1) the secondary use of anti- United States and accounted for 29,900 deaths in 2003.1 androgens (e.g., high-dose bicalutamide, nilutamide), (2) thera- Although most men with advanced prostate cancer respond pies targeted against adrenal steroid synthesis (e.g., ketocona- initially to androgen deprivation therapies (ADT) by either zole, corticosteroids), and (3) estrogenic therapies (e.g. diethy- bilateral orchiectomy or leuteinizing hormone releasing hor- lstilbestrol). Symptomatic improvement and PSA responses mone (LHRH) analogues, patients eventually progress to an (defined as PSA decline ＞50% after treatment) have been androgen-independent state in which the initial ADT no longer reported in approximately 20% to 80% of patients with is adequate to control disease.2 Progression of the disease hormone-refractory prostate cancer (HRPC) with a typical manifests as an increase in serum prostate-specific antigen duration of response of 2 to 6 months. Toxicity is generally (PSA) or may be accompanied by radiographic evidence of mild for these oral therapies, although serious side effects, tumor growth. Here we report a brief summary of recent including adrenal insufficiency, liver toxicity, and thrombosis, advances in the management of hormone refractory prostate may occur (Table 1).
    [Show full text]